FGFR2 and infantile convulsions and choreoathetosis: More recently, futibatinib, an irreversible FGFR1–4 inhibitor, demonstrated an mPFS of 8.9 months and mOS of 20.0 months in a phase II study and received FDA approval in 2022 for iCCA patients with FGFR2 fusions or other alterations (Table 1) [40].